Arbutus Biopharma (ABUS) Assets (2010 - 2026)

Arbutus Biopharma has disclosed Assets across 17 years of filings, most recently posting $277.2 million for Q1 2026.

• Assets for Q1 2026 came in at $277.2 million, up 136.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $277.2 million (up 136.87% YoY), and the FY2025 annual result was $94.6 million, down 28.16% from the prior year.
• Assets came in at $277.2 million for Q1 2026 at Arbutus Biopharma, up from $94.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $277.2 million in Q1 2026 to a low of $94.6 million in Q4 2025.
• The 5-year median for Assets is $158.6 million (2023), against an average of $164.4 million.
• Across the five-year window, Assets plunged 35.48% in 2025 and surged 136.87% in 2026, its largest moves.
• Arbutus Biopharma's Assets stood at $195.4 million in 2022, then slipped by 26.11% to $144.4 million in 2023, then decreased by 8.79% to $131.7 million in 2024, then dropped by 28.16% to $94.6 million in 2025, then surged by 192.93% to $277.2 million in 2026.
• The last three Assets figures came in at $277.2 million (Q1 2026), $94.6 million (Q4 2025), and $97.7 million (Q3 2025), per Business Quant data.